Kim Young Jae, Lee Mi Young, Won Chong Hyun
Department of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Asia Pac Allergy. 2022 Jan 10;12(1):e1. doi: 10.5415/apallergy.2022.12.e1. eCollection 2022 Jan.
Dupilumab, a monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adult patients with moderate-to-severe atopic dermatitis, inhibits interleukins 4 and 13. It is an effective treatment option for atopic dermatitis, but facial redness has been reported as an unexpected adverse effect. Although several theories have been proposed to explain the facial redness caused by dupilumab, the underlying mechanism is yet to be verified. To the best of our knowledge, to date, only few reports have described erythema appearance on nonfacial areas after dupilumab treatment. Herein, we report the cases of 3 patients who presented with erythema on their hands and feet after dupilumab injections. The erythema persisted, even when the atopic dermatitis lesions improved. Additional reports are needed to demonstrate the clinical characteristics of postdupilumab acral erythema.
度普利尤单抗是一种经美国食品药品监督管理局批准用于治疗中度至重度特应性皮炎成年患者的单克隆抗体，可抑制白细胞介素4和13。它是治疗特应性皮炎的一种有效选择，但面部发红已被报道为一种意外的不良反应。尽管已经提出了几种理论来解释度普利尤单抗引起的面部发红，但其潜在机制尚待证实。据我们所知，迄今为止，只有少数报告描述了度普利尤单抗治疗后非面部区域出现红斑的情况。在此，我们报告3例患者在注射度普利尤单抗后手脚出现红斑的病例。即使特应性皮炎皮损有所改善，红斑仍持续存在。需要更多报告来证明度普利尤单抗治疗后手足红斑的临床特征。
